Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;15(1):47-53.
doi: 10.1007/s12253-008-9086-0. Epub 2008 Aug 28.

Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor

Affiliations
Free article

Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor

Béla Csete et al. Pathol Oncol Res. 2009 Mar.
Free article

Abstract

Poly(adenosine diphosphate-ribose) polymerases (PARPs) are a family of enzymes, which catalyses poly (ADP-ribosyl)ation of DNA-binding proteins and directly involved in genomic stability, DNA repair, and apoptosis. In this study, we evaluated the immunomorphology of PARP-1 in melanoma and its prognostic importance. We studied PARP-1 expression by immunohistochemistry in a selected series of 54 primary cutaneous malignant melanoma (CMM). The findings of the present study suggest that the neoplastic progression toward the invasive (both horizontal and vertical) growth phase of CMM cells is characterized by the loss of cleavage of PARP-1, probably signaling an imbalance of the apoptotic process in these cells and leading to further gain to aggression. Over-expression of full-length PARP-1 was correlated with recurrence and/or progression of the disease and so act as a promising new biological marker of CMM. Our study represents the evidence of a direct correlation between the PARP-1-mediated apoptotic process and the biologic behavior of CMM.

PubMed Disclaimer

References

    1. Clin Cancer Res. 1998 Aug;4(8):1865-71 - PubMed
    1. J Cell Sci. 2005 Feb 1;118(Pt 3):589-99 - PubMed
    1. Versicherungsmedizin. 1994 Dec 1;46(6):193-5 - PubMed
    1. Anticancer Res. 2002 May-Jun;22(3):1635-9 - PubMed
    1. Science. 1995 Mar 10;267(5203):1445-9 - PubMed

MeSH terms

Substances